DFDA

Sertraline (SSRI)

Treatment for Premenstrual Syndrome

Typical Dosage: 25-50mg daily

Effectiveness
78%
Safety Score
60%
Clinical Trials
1
Participants
9K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
25-50mg daily
Time to Effect
1-2 weeks
Treatment Duration
Continuous or luteal phase
Evidence Quality
HIGH
Number Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
9(Treat 9 patients to see 1 additional serious adverse event)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$80
Monitoring:$100
Side Effect Mgmt:$55
Total Annual:$235
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$48,000/QALY
QALYs Gained
0.09
Outcome-Based Costs
Cost per Responder
$346
Cost per Remission
$618
Comparison vs Placebo
Cost Difference
+$235/year
More expensive
QALY Difference
+0.09 QALYs
Better outcomes
Dominance
No dominance
Sertraline (SSRI) Outcomes

for Premenstrual Syndrome

Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+68%
Remission Rate
+38%
Common Side Effects
Nausea
+25%
Diarrhea
+18%
Sexual dysfunction
+35%
Insomnia
+12%

Sources:

nih.gov
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for Sertraline (SSRI) in Premenstrual Syndrome

Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

NCT06704594RECRUITINGPHASE4
View Study
288 participants
INTERVENTIONAL
Baltimore, United States +1 more
Started: May 14, 2025